ClinicalTrials.gg
RecruitingNCT07079722MHLDUpdated Jul 23, 2025

More Health Less Diabetes

An interventional study of Exercise in Pre-diabetes, sponsored by Faculdade de Motricidade Humana. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Faculdade de Motricidade Humana · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The "More Health, Less Diabetes" project is a hybrid randomized controlled trial to prevent type 2 diabetes in individuals at risk through structured exercise and lifestyle education. While exercise benefits for people with diabetes are well-documented, evidence remains limited on the effectiveness and cost-effectiveness of in-person and home-based exercise programs in a prediabetic population. This study aims to understand the clinical and cost-effectiveness of a three-arm RCT (online, in-person, and a control group) in people at high risk of developing T2DM. This 12-month program includes six months of supervised exercise (3 times/week) and a six-month follow-up. During the first six months, both intervention groups will attend educational sessions to improve health literacy and promote healthy habits. The primary outcome will be 2h glycemia in an oral glucose tolerance test. Secondary outcomes include other aspects of glycemic control (HbA1c, fasting glycemia, HOMA-IR, Matsuda index), 24-hour movement, body composition, vascular health, physical fitness, and cost-effectiveness using a social return on investment approach.

Read the detailed description

Introduction

Diabetes is a major public health concern affecting approximately 11.1% of the adult population (588.7 million people), with projections suggesting an increase to 852 million by 2050. In Portugal, diabetes affects approximately 14.1% of the population between 20-79 years, with an additional 28.6% of the Portuguese population having intermediate hyperglycemia. These alarming values result in a financial burden for the Portuguese healthcare system, with annual costs ranging between 6-7% of total Portuguese healthcare cost.

On this note, there is evidence that 70% of people with intermediate hyperglycemia tend to develop type 2 diabetes mellitus (T2DM) in a 10- year follow-up . Risk factors, such as higher BMI and waist circumference values, physical inactivity, unhealthy diet, and poor health literacy, are directly associated with the development of T2DM. Furthermore, from the early stages of pre-diabetes, there is strong evidence of structural and functional vascular changes, which are known to increase in the medium to long/term micro and macrovascular complications.

From an economic and public health perspective, exercise interventions in a community setting are worth investing for T2DM management and prevention. The Diabetes Prevention Program (DPP) reported that 5-7% individuals who met the physical activity goals reduced their incidence of T2DM by 44% - even without weight loss. The 15-year follow-up study of the DPP has also provided evidence of the superior impact of a lifestyle intervention for preventing the development of DMT2 compared to just medication. Furthermore, our group has also shown the importance of exercise in improving health-related biomarkers in people with T2DM. Despite its known benefits, evidence suggests that comparability across exercise interventions is limited due to several issues, such as heterogeneity in intervention type, design, and delivery. For instance, studies have explored the impact of online or in-person regimes to address how lifestyle interventions should be delivered. The current body of literature on online interventions suggests that the improvements in health-related outcomes and adherence may be compromised in the medium to long term. However, online interventions are known to be more scalable and less expensive than in-person programs. On the other hand, evidence from national in-person programs, such as the "Diabetes em Movimento" program, has shown that community-based exercise programs can significantly improve cardiometabolic parameters and still be cost-effective in people with T2DM. This program is currently implemented in 52 Portuguese municipalities. Despite the effectiveness and cost-effectiveness of such exercise programs on the T2DM population, there is a gap of experimental evidence of how in-person or online lifestyle programs impact those at risk of developing T2DM. Thus, it is crucial to develop a proof-of-concept, evidence-based exercise program tailored to individuals at risk of T2DM that can ultimately be scaled to reduce the burden of T2DM at a population level. Implementing a hybrid randomized controlled trial would allow for a comprehensive cost- effectiveness evaluation, helping to determine whether online or in-person delivery yields the most economically viable and clinically beneficial outcomes.

Aims

1. To analyze the clinical effectiveness of a 6-month online regime vs. in-person lifestyle intervention vs. controls on post-prandial 2h glucose in an OGTT in people at an increased risk of developing type 2 diabetes and its impact at a 12-month follow-up period.

Secondary:

  1. To evaluate the cost-effectiveness of the intervention with exercise and educational sessions, using a social return on investment approach (SROI) in an online regime vs. an in-person regime vs. a control group at the 6-month and 12-month periods
  2. Assess differences at the 6-month intervention and 12-month follow-up period in other aspects of glycemic control (HOMA-IR, Matsuda index), body composition regional and total outcomes, structural and functional vascular health, handgrip strenght, 24-hour movement variables, and quality of life in the different intervention arms (e.g., In-person, online, and control).

Recruitment

Participants will be recruited for an interventional study targeting individuals with prediabetes or a high-to-very-high risk of Type 2 Diabetes, based on risk stratification using the FINDRISC questionnaire. Recruitment will take place through primary healthcare consultations in the Oeiras municipality. Individuals diagnosed with Diabetes Mellitus, those who underwent a diabetes risk assessment more than three years ago, or those with a confirmed diagnosis of diabetes will be excluded. Power calculations and sample size estimation (G-Power, Version 3.1.3) were based on an effect size of 0.2 for the Finnish Diabetes Risk Score (FINDRISC), with α = 0.05 and a power of 0.80. The final sample will consist of 90 participants, accounting for an expected dropout rate of 30%.

Study Design

The "More Health, Less Diabetes" research project is a randomized controlled trial (RCT) with three distinct groups: a control group (CG), an online intervention group (OIG), and an in-person intervention group (IIG). The OIG will receive online educational sessions and structured home-based exercises, while the IIG will participate in in-person educational sessions and supervised physical exercise. The control group will not participate in educational sessions or structured physical exercise.

The intervention will last six months across all groups, with additional follow-up assessments at 12 months. No educational sessions will occur during the follow-up period, and exercise will be optional for all groups. During this phase, control group participants may also join exercise sessions.

Randomization will be automated and conducted by a team member not directly involved in data collection or intervention processes. The Redcap® platform will be used for randomization, ensuring a 1:1:1 allocation ratio stratified by age.

Laboratory Analyses

Biochemical assessments will be conducted through primary healthcare centers. Participants will undergo clinical analyses of glycated hemoglobin (HbA1c) and fasting blood glucose, as well as a 2-hour glucose tolerance test (OGTT) after ingesting 75g of glucose at baseline, after six months, and after one year.

Anthropometric Measurements

Participants' weight and height will be measured with a precision of 0.01 kg and 0.1 cm, respectively, using a scale with an integrated stadiometer (Seca, Hamburg, Germany). Body Mass Index (BMI) will be calculated using the formula [weight (kg)/height² (m²)]. Measurements will be collected at baseline, six months, and one year.

Bioelectrical Impedance Analysis

Whole-body bioelectrical impedance analysis (BIA) will be performed using the AKERN BIA 101/BIVA PRO device, a phase-sensitive single-frequency BIA device. Participants will be instructed to lie down for 10 minutes before measurement. After cleaning the skin, eight low-impedance electrodes (Biatrodes, Akern Srl, Florence, Italy) will be placed on the dorsal surfaces of the feet, ankles, wrists, and hands. This analysis will be performed at baseline, after six months, and after one year.

Dual-Energy X-ray Absorptiometry (DXA)

Lean body mass and fat mass will be determined for the whole body and regionally using dual-energy X-ray absorptiometry (DXA; Hologic Explorer W, QDR for Windows version 12.4, Waltham, MA, USA). This evaluation will be conducted at baseline, after six months, and after one year.

Maximal Cardiopulmonary Exercise Testing

A maximal cardiopulmonary exercise test will be used to assess peak aerobic capacity, peak power output (PPO), and pre-existing cardiac conditions. A ramp incremental protocol will be performed to exhaustion on a cycle ergometer (Monark 839E, Kroons Vag, Sweden). Workload will start at 20 Watts/min and increase in increments of 5-20 Watts/min, based on individual cardiopulmonary responses in the first minute, with a constant cadence of 60 rpm. A cardiologist will monitor all tests using a 12-lead electrocardiogram, and additional data, including heart rate, will be recorded using Omnia software (Cosmed, Rome, Italy). Expired and inspired gases will be continuously analyzed using a Quark RMR w/CPET gas analyzer (version 9.1, Cosmed, Rome, Italy).

Handgrip Strength

The handgrip strength will be accessed using a dynamometer (JAMAR), which measures the upper limb strength and can estimate an individual's total strength.

Vascular Health

Vascular functional health will be measured via pulse wave velocity on the carotid-femoral, carotid-radial, and femoral dorsalis sites (Complior, Alam Medical, France). Structural indices will be assessed via intima-media thickness and arterial stiffness using ultrasonography of the right common carotid artery (Arietta V60, Hitachi Aloka, Japan).

02

Conditions studied

  • Pre-diabetes

Keywords

  • Diabetes
  • Exercise
  • Community programs
  • Prevention
  • Health
03

In context

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 113 are open to participants now.

This study's planned enrollment of 90 is above the median of 56 across 660 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

Faculdade de Motricidade Humana is the lead sponsor of 22 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. High or Very High Risk according to the FINDRISC questionnaire;
  2. Analytical confirmation of no diagnostic criteria for Diabetes, following a type 2 Diabetes risk assessment;
  3. Committed to making lifestyle changes to manage diabetes;
  4. Internet access;
  5. Availability to participate in the program as required (schedule, location);

Exclusion criteria

Exclusion Criteria:

  1. pregnancy (self-report/medical record);
  2. Inability to use digital devices
  3. Presence of abnormalities on exercise stress test.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Control group

    The control group will not participate in educational sessions or structured physical exercise.

    Behavioral: Exercise

  • Experimental
    In-person intervention group (IIG).

    The IIG will participate in in-person educational sessions and supervised physical exercise

    Behavioral: Exercise

  • Experimental
    Online intervention group (OIG)

    The OIG will receive online educational sessions and structured home-based exercises

    Behavioral: Exercise

Interventions

  • BehavioralExercise

    This project is a randomized controlled trial (RCT) with three distinct groups: a control group (CG), an online intervention group (OIG), and an in-person intervention group (IIG). The OIG will receive online educational sessions and structured home-based exercises, while the IIG will participate in in-person educational sessions and supervised physical exercise. The control group will not participate in educational sessions or structured physical exercise.

06

What researchers measure

Primary outcomes

  1. 2-hour glucose tolerance test (OGTT)

    Biochemical assessments will be conducted through primary healthcare centers. Participants will undergo clinical analyses of a 2-hour glucose tolerance test (OGTT) after ingesting 75g of glucose at baseline, after six months, and after one year.

    Time frame: 1 year

Secondary outcomes

  1. Height in centimeters

    Participants' height will be measured with a precision of 0.1 cm, using a scale with an integrated stadiometer (Seca, Hamburg, Germany). Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  2. Weight in kilograms

    Participants' weight will be measured with a precision of 0.01 kg, using a scale with an integrated stadiometer (Seca, Hamburg, Germany). Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  3. Body Mass Index

    Body Mass Index (BMI) will be calculated using the formula \[weight (kg)/height² (m²)\]. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  4. Effectiveness of the program

    The primary effectiveness outcome will be the change in 2-hour glucose OGTT levels.

    Time frame: Through study completion, an average of 1 year

  5. Costs of the program

    The total cost of the program will be calculated by summing direct costs (e.g., facility use, instructor fees, and equipment) and indirect costs (e.g., participant time and transportation, where applicable).

    Time frame: Through study completion, an average of 1 year

  6. Cost-effectiveness

    Cost-effectiveness will be assessed using the Social Return on Investment framework, which estimates the social value generated for each monetary unit invested. This outcome measure will combine cost and effectiveness of the program.

    Time frame: Through study completion, an average of 1 year

  7. Glycated Hemoglobin

    Biochemical assessments will be conducted through primary healthcare centers. Participants will undergo clinical analyses of glycated hemoglobin (HbA1c).Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  8. Fasting blood glucose

    Biochemical assessments will be conducted through primary healthcare centers. Participants will undergo clinical analyses of fasting blood glucose. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  9. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    HOMA-IR will be calculated to estimated insulin resistance. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  10. Matsuda Index

    Matsuda Index will be calculated to assess insulin sensitivity. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  11. Bioelectrical Impedance Analysis

    Whole-body bioelectrical impedance analysis (BIA) will be performed using the AKERN BIA 101/BIVA PRO device, a phase-sensitive single-frequency BIA device. Participants will be instructed to lie down for 10 minutes before measurement. After cleaning the skin, eight low-impedance electrodes (Biatrodes, Akern Srl, Florence, Italy) will be placed on the dorsal surfaces of the feet, ankles, wrists, and hands. This analysis will be performed at baseline, after six months, and after one year.

    Time frame: 1 year

  12. Maximal Cardiopulmonary Exercise Testing

    A maximal cardiopulmonary exercise test will be used to assess peak aerobic capacity, peak power output (PPO), and pre-existing cardiac conditions. A ramp incremental protocol will be performed to exhaustion on a cycle ergometer (Monark 839E, Kroons Vag, Sweden). Workload will start at 20 Watts/min and increase in increments of 5-20 Watts/min, based on individual cardiopulmonary responses in the first minute, with a constant cadence of 60 rpm. A cardiologist will monitor all tests using a 12-lead electrocardiogram, and additional data, including heart rate, will be recorded using Omnia software (Cosmed, Rome, Italy). Expired and inspired gases will be continuously analyzed using a Quark RMR w/CPET gas analyzer (version 9.1, Cosmed, Rome, Italy). Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  13. Dual-Energy X-ray Absorptiometry (DXA)

    Lean body mass and fat mass will be determined for the whole body and regionally using dual-energy X-ray absorptiometry (DXA; Hologic Explorer W, QDR for Windows version 12.4, Waltham, MA, USA). This evaluation will be conducted at baseline, after six months, and after one year.

    Time frame: 1 year

  14. Handgrip Strenght

    The handgrip strength will be accessed using a dynamometer (JAMAR), which measures the upper limb strength and can estimate an individual's total strength. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  15. Vascular Health-pulse wave velocity

    Vascular functional health will be measured via pulse wave velocity on the carotid-femoral, carotid-radial, and femoral dorsalis sites (Complior, Alam Medical, France). Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  16. Vascular structural indices- Arterial Stiffness

    Structural indices will be assessed viaarterial stiffness using ultrasonography of the right common carotid artery (Arietta V60, Hitachi Aloka, Japan). Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  17. Vascular structural indices- Intima-media thickness

    Structural indices will be assessed via intima-media thickness using ultrasonography of the right common carotid artery (Arietta V60, Hitachi Aloka, Japan). Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  18. GRAFFAR Questionnaire

    GRAFFAR questionnaire will be used to assess the socioeconomic status of the participants. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  19. FINDRISC Questionnaire

    FINDRISC questionnaire will be used to assess participants' risk of developing type 2 diabetes. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  20. EQ-5D-5L Questionnaire

    EQ-5D-5L questionnaire will be used to assess participants' quality of life. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  21. IPAQ Questionnaire

    Adapted IPAQ questionnaire will be used to assess participants' physical activity level. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

  22. PREDIMED Questionnaire

    PREDIMED questionnaire will be used to assess participants' diet. Measurements will be collected at baseline, six months, and one year.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75. doi: 10.1016/S2213-8587(15)00291-0. Epub 2015 Sep 13. PubMed 26377054 ↗
  • Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th edition. Brussels: International Diabetes Federation; 2021. Available from http://www.ncbi.nlm.nih.gov/books/NBK581934/ PubMed 35914061 ↗
  • Al Ozairi E, Alsaeed D, Al Roudhan D, Jalali M, Mashankar A, Taliping D, Abdulla A, Gill JMR, Sattar N, Welsh P, Gray SR. The effect of home-based resistance exercise training in people with type 2 diabetes: A randomized controlled trial. Diabetes Metab Res Rev. 2023 Oct;39(7):e3677. doi: 10.1002/dmrr.3677. Epub 2023 Jun 17. PubMed 37330638 ↗
  • Dunstan DW, Daly RM, Owen N, Jolley D, Vulikh E, Shaw J, Zimmet P. Home-based resistance training is not sufficient to maintain improved glycemic control following supervised training in older individuals with type 2 diabetes. Diabetes Care. 2005 Jan;28(1):3-9. doi: 10.2337/diacare.28.1.3. PubMed 15616225 ↗
  • Dunstan DW, Vulikh E, Owen N, Jolley D, Shaw J, Zimmet P. Community center-based resistance training for the maintenance of glycemic control in adults with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2586-91. doi: 10.2337/dc06-1310. PubMed 17130189 ↗
  • Golovaty I, Wadhwa S, Fisher L, Lobach I, Crowe B, Levi R, Seligman H. Reach, engagement and effectiveness of in-person and online lifestyle change programs to prevent diabetes. BMC Public Health. 2021 Jul 5;21(1):1314. doi: 10.1186/s12889-021-11378-4. PubMed 34225674 ↗
  • Correia IR, Hetherington-Rauth M, Magalhaes JP, Judice PB, Rosa GB, Henriques-Neto D, Manas A, Ara I, Silva AM, Sardinha LB. Compensatory mechanisms from different exercise intensities in type 2 diabetes: a secondary analysis of a 1-year randomized controlled trial. Acta Diabetol. 2023 May;60(5):645-654. doi: 10.1007/s00592-023-02038-7. Epub 2023 Feb 2. PubMed 36729308 ↗
  • Magalhaes JP, Hetherington-Rauth M, Judice PB, Correia IR, Rosa GB, Henriques-Neto D, Melo X, Silva AM, Sardinha LB. Interindividual Variability in Fat Mass Response to a 1-Year Randomized Controlled Trial With Different Exercise Intensities in Type 2 Diabetes: Implications on Glycemic Control and Vascular Function. Front Physiol. 2021 Sep 16;12:698971. doi: 10.3389/fphys.2021.698971. eCollection 2021. PubMed 34603073 ↗
  • Mendes R, Sousa N, Reis VM, Themudo-Barata JL. Implementing Low-Cost, Community-Based Exercise Programs for Middle-Aged and Older Patients with Type 2 Diabetes: What Are the Benefits for Glycemic Control and Cardiovascular Risk? Int J Environ Res Public Health. 2017 Sep 13;14(9):1057. doi: 10.3390/ijerph14091057. PubMed 28902144 ↗
  • Magalhaes JP, Melo X, Correia IR, Ribeiro RT, Raposo J, Dores H, Bicho M, Sardinha LB. Effects of combined training with different intensities on vascular health in patients with type 2 diabetes: a 1-year randomized controlled trial. Cardiovasc Diabetol. 2019 Mar 18;18(1):34. doi: 10.1186/s12933-019-0840-2. PubMed 30885194 ↗
  • Magalhaes JP, Judice PB, Ribeiro R, Andrade R, Raposo J, Dores H, Bicho M, Sardinha LB. Effectiveness of high-intensity interval training combined with resistance training versus continuous moderate-intensity training combined with resistance training in patients with type 2 diabetes: A one-year randomized controlled trial. Diabetes Obes Metab. 2019 Mar;21(3):550-559. doi: 10.1111/dom.13551. Epub 2018 Oct 29. PubMed 30284352 ↗
  • Hetherington-Rauth M, Magalhaes JP, Judice PB, Melo X, Sardinha LB. Vascular improvements in individuals with type 2 diabetes following a 1 year randomised controlled exercise intervention, irrespective of changes in cardiorespiratory fitness. Diabetologia. 2020 Apr;63(4):722-732. doi: 10.1007/s00125-020-05089-5. Epub 2020 Jan 20. PubMed 31960071 ↗
  • Magalhaes JP, Santos DA, Correia IR, Hetherington-Rauth M, Ribeiro R, Raposo JF, Matos A, Bicho MD, Sardinha LB. Impact of combined training with different exercise intensities on inflammatory and lipid markers in type 2 diabetes: a secondary analysis from a 1-year randomized controlled trial. Cardiovasc Diabetol. 2020 Oct 7;19(1):169. doi: 10.1186/s12933-020-01136-y. PubMed 33028418 ↗
  • Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006 Sep;29(9):2102-7. doi: 10.2337/dc06-0560. PubMed 16936160 ↗
  • Barbosa A, Brito J, Figueiredo P, Seabra A, Ding D, Mendes R. How much does it cost to implement a community-based walking football programme for patients with type 2 diabetes? BMJ Open Sport Exerc Med. 2023 Jun 7;9(2):e001549. doi: 10.1136/bmjsem-2023-001549. eCollection 2023. PubMed 37304893 ↗
  • Green DJ, Hopman MT, Padilla J, Laughlin MH, Thijssen DH. Vascular Adaptation to Exercise in Humans: Role of Hemodynamic Stimuli. Physiol Rev. 2017 Apr;97(2):495-528. doi: 10.1152/physrev.00014.2016. PubMed 28151424 ↗
  • Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circ Res. 2018 Apr 13;122(8):1135-1150. doi: 10.1161/CIRCRESAHA.118.311912. PubMed 29650631 ↗
  • Ligthart S, van Herpt TT, Leening MJ, Kavousi M, Hofman A, Stricker BH, van Hoek M, Sijbrands EJ, Franco OH, Dehghan A. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2016 Jan;4(1):44-51. doi: 10.1016/S2213-8587(15)00362-9. Epub 2015 Nov 11. PubMed 26575606 ↗
  • Beulens J, Rutters F, Ryden L, Schnell O, Mellbin L, Hart HE, Vos RC. Risk and management of pre-diabetes. Eur J Prev Cardiol. 2019 Dec;26(2_suppl):47-54. doi: 10.1177/2047487319880041. PubMed 31766914 ↗
  • Diabetologia SPd. Diabetes: Factos e Números- O ano de 2019, 2020 e 2021- Relatório Anual do Observatório Nacional de Diabetes. 2023.
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jul 2026, 10 months later.

Of 253 non-industry interventional studies with no phase under Glucose Intolerance, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 10 months is below that.

Counting every sponsor, half of 285 studies reached it within 26 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jul 23, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Jul 30, 2026
CompletionEst.
Dec 20, 2026
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07079722
Lead sponsor
Faculdade de Motricidade Humana
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Jul 30, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Jul 23, 2025

Study contacts

João Magalhães Associate Professor, Doctor
Contact
joaomagalhaes@fmh.ulisboa.pt
967 832 539 ext. +351

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion